Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

PARIS May 1 9 , 20 21 – New research being presented at the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8 highlights Sanofi’s transformative science and commitment to patient care across difficult-to-treat cancers, including multiple myeloma, skin, lung and breast cancers.

Our pipeline of innovative investigational medicines continues to expand, supporting our goalto address critical gaps in treatment optionsfor patients with cancersof high unmet need,” says Peter C. Adamson, Global Development Head, Oncology at Sanofi. We look forward to presenting the latest dataacross our oncology portfolio and pipeline in four key areas – multiple myeloma, skin cancers, lung cancers and breast cancer, including data supporting the potential for amcenestrant to become a best-in-class oral endocrine backbone therapy.”

Early clinical data for amcenestrant, our i nvestigational oral selective estrogen receptor degrader ( SERD ) , show p otential to be come a new endocrine backbone therapy in ER+ HER2- breast cancer *

Click here to read the full amcenestrant data press release issued by Sanofi.

Data analyses reinforce Libtayo ® (cemiplimab-rwlc) as a standard of care in advanced non-melanoma skin cancer indications and in advanced non-small cell lung cancer , including new data in historically underrepresented patients with brain metastases

Libtayo in N on-melanoma Skin Cancer

Other Sanofi s tudies in Non -Melanoma Skin Cancer

Libtayo in Non-small Cell Lung Cancer

Libtayo is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

Longer term data and new analyses for Sarclisa ® (isatuximab-irfc) further strengthen its efficacy profile, including for elderly patients and patients with high - risk cytogenetic abnormalities

Biomarker research for t usamitamab ravtansine , an e arly-stage , potential first-in-class investigational anti-CEACAM5 antibody drug conjugate for advanced non-small cell lung cancer *

Safety, pharmacokinetic and pharmacodynamic data with our investigational transforming growth factor beta (TGF- b ) *

Early data with investigational anti-ICOS antibody, KY1044, submitted by Kymab , a Sanofi company *

Independent research supported by Sanofi

Jevtana (Cabazitaxel)
Abstract 5059 First results from a randomized Phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
Abstract 1008 Randomised multicentre trial of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metastatic breast cancer (MBC)
Abstract e17027 Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: interim analysis of efficacy endpoints

Click here to view these abstracts along with the full digital program located in the ASCO Meeting Library.

*These assets are currently under investigation and their safety and efficacy has not been fully evaluated by any health authority.


About Sanofi


Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.


With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.


Sanofi, Empowering Life


Sanofi Media Relations Contact
Sally Bain
Tel.: +1 (781) 264-1091
[email protected]












Sanofi Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine


Sanofi Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco


Sanofi IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]

    Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.